血浆脑源性神经营养因子水平与阿尔茨海默病不同阶段的关系：一项横断面研究。

Association of plasma BDNF levels with different stages of Alzheimer's disease: a cross-sectional study.

机构信息

Department of Biobank, Xuanwu Hospital of Capital Medical University, Beijing, China.

National Clinical Research Center for Geriatric Disorders, Xuanwu Hospital of Capital Medical University, Beijing, China.

出版信息

Neurol Res. 2023 Mar;45(3):234-240. doi: 10.1080/01616412.2022.2129760. Epub 2022 Dec 1.

DOI:10.1080/01616412.2022.2129760

PMID:36453692

Abstract

BACKGROUND

Growing evidence shows that the expression of brain-derived neurotrophic factor (BDNF) is altered in the peripheral blood of participants with Alzheimer's disease (AD). It is unclear, however, whether altered BDNF expression is also observed in the early stages of AD.

METHODS

In the present study, 138 normal controls (NC), 57 participants with subjective cognitive decline (SCD), and 37 participants with amnestic mild cognitive impairment (aMCI) and AD were included. Plasma BDNF protein levels were assessed using a commercial multiplex Luminex-based kit. Patient samples were also probed for the presence of gene variant .

RESULTS

Pairwise comparisons between the groups showed that there was not a significant difference in BDNF levels when comparing SCD with NC and when comparing SCD with aMCI/AD, but BDNF levels in aMCI/AD samples were increased when compared with NC samples. For models differentiating clinical groups, discriminant analysis was performed by including education, genotype, and BDNF levels in the model. This approach distinguishes participants with SCD (AUC = 0.630) and aMCI/AD (AUC = 0.665) from NC.

CONCLUSION

Our results suggest that expression of BDNF in plasma is altered at the clinical stage of AD.

摘要

背景

越来越多的证据表明，阿尔茨海默病（AD）患者外周血中脑源性神经营养因子（BDNF）的表达发生改变。然而，AD 的早期阶段是否也观察到 BDNF 表达的改变尚不清楚。

方法

本研究纳入了 138 名正常对照（NC）、57 名主观认知下降（SCD）患者和 37 名遗忘型轻度认知障碍（aMCI）和 AD 患者。使用商业的基于多重 Luminex 的试剂盒评估血浆 BDNF 蛋白水平。还对患者样本进行了基因变异的探测。

结果

组间的两两比较显示，SCD 与 NC 之间以及 SCD 与 aMCI/AD 之间的 BDNF 水平没有显著差异，但与 NC 样本相比，aMCI/AD 样本中的 BDNF 水平升高。对于区分临床组的模型，通过在模型中包含教育、基因型和 BDNF 水平来进行判别分析。这种方法可以区分 SCD（AUC=0.630）和 aMCI/AD（AUC=0.665）患者与 NC。